Abstract��OBJECTIVE To introduce international reimbursement policies on drugs for pulmonary arterial hypertension (PAH), and provide a reference for establishing relevant policies in China. METHODS Reimbursement policies on PAH drugs of Australia, Canada, America and some EU countries were analyzed and compared with the status quo in China. RESULTS Although expensive, PAH drugs are reimbursed by medical insurance in most countries included in this study. However, the accessibility of PAH drugs in China remains very poor with only a few cities including these drugs in the medical insurance. Patients with PAH face with poverty caused by disease, even abandoning treatment. CONCLUSION Learning the experience from countries with rare disease act and good medical insurance system and analysing the earliest attempts to reimburse PAH drugs in China will help promote the reimbursement policy on PAH drugs in China.
HUMBER M, SITBON O, CHAOUAT A, et al. Pulmonary arterial hypertension in France: Results from a national registry[J]. Am J Respir Crit Care Med, 2006, 173(9): 1023-1230.
[2]
TUELLER C, STRICKER H, SOCCAL P, et al. Epidemiology of pulmonary hypertension: New data from the Swiss registry[J]. Swiss Med Wkly, 2008, 138 (25-26): 379-384.
[3]
PEACOCK A J, MURPHY N F, MCMURRAY J J, et al. An epidemiological study of pulmonary arterial hypertension[J]. Eur Respir J, 2007, 30 (1): 104-109.
[4]
Expert consensus of screening, diagnosis and treatment of pulmonary hypertension[J]. Chin J Cardiol(�л���Ѫ�ܲ���־), 2007,35(11):979-987.
[5]
SUN Y J. Pulmonary hypertension targeted therapy and prognosis[D]. Peking Union Medical College,2012.
[6]
Beijing ISEEKPH Pulmonary hypertension Rare Disease Care Center. Pulmonary Hypertension social support and health care policy seminar [Z].Beiing, 2014.5.
[7]
BLANKART C R, STARGARDT T, SCHREY�WGG J. Availability of and access to orphan drugs: An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angioedema and chronic myeloid leukaemia[J]. Pharmacoeconomics,2011, 29(1):63-82.
[8]
DING J X, JI N, BAI G L. Policy research on orphan drug market security in China[J]. Chin J Pharm(�й�ҽҩ��ҵ��־),2012,43(11):959-965.
[9]
Fees, Patient Contributions and Safety Net Thresholds [EB/OL]. The Pharmaceutical Benefits Scheme(PBS), 2015, (2015-07-01)[2015-07-24]. http://www.pbs.gov.au/info/healthpro/explanatory-notes/front/fee.
[10]
Highly Specialised Drugs Programme: Private Hospital Dispensed National Expenditure Report (Previous 2 Years and Current Year to Date)[EB/OL]. The Pharmaceutical Benefits Scheme(PBS).[2015-02-12]. http://www.pbs.gov.au/info/statistics/hsd-expenditure-reports/hsd-private-hospital-expenditure.
[11]
Highly Specialised Drugs Programme: Public Hospital Dispensed National Expenditure Report (Previous 2 Years and Current Year to Date)[EB/OL]. The Pharmaceutical Benefits Scheme(PBS).[2015-02-12]. http://www.pbs.gov.au/info/statistics/hsd-expenditure-reports/hsd-public-hospital-expenditure.
[12]
ZHANG R, DAI L Z, XIE W P, et al. Survival of Chinese patients with pulmonary arterial hypertension in the modern treatment era[J]. Chest, 2011, 140(2):301-309.
[13]
LIANG T K, SHANG K. Qingdao modes: Practice and prospects for rare disease medical security system[J].Social Security Studies,2014,(3):64-73.
2015, Vol. 50 
